Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis
نویسندگان
چکیده
منابع مشابه
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease
There is a pressing, global need for new therapies for neglected diseases such as Tuberculosis, Leishmaniasis and Chagas. Traditional lead discovery approaches, while effective have not been widely applied to neglected diseases as they are expensive and time consuming. At Institut Pasteur Korea, we have developed a core technology that enables the high content screening of hundreds of thousands...
متن کاملDiscovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis
The protozoan parasite Trypanosoma brucei causes the fatal illness human African trypanosomiasis (HAT). Standard of care medications currently used to treat HAT have severe limitations, and there is a need to find new chemical entities that are active against infections of T. brucei. Following a "drug repurposing" approach, we tested anti-trypanosomal effects of carbazole-derived compounds call...
متن کاملErratum: Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the mater...
متن کاملRepurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery.
W ith the rise in resistance that inevitably follows the clinical deployment of an antibiotic, there is a continual need for new antibiotic discovery, development and approval. Food and Drug Administration approvals for Synercid (quinupristin/dalfopristin) in 1999, Zyvox (linezolid) in 2000, and Cubicin (daptomycin) in 2003 have addressed life-threatening infections from drug-resistant Gram-pos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Medicinal Chemistry
سال: 2013
ISSN: 0022-2623,1520-4804
DOI: 10.1021/jm400349k